Home / Stocks / Sakar Healthcare Limited
SAKAR

Sakar Healthcare Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹976.2

Change

-33.5 (-3.32%)

Open

₹1,009.0

Prev. Close

₹1,009.7

Day High

₹1,020.45

Day Low

₹960.05

Volume Analysis

Traded

103,338

Delivered

58,242

Delivery %

56.36%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (30.0%)

Weaknesses (2)

  • •Low return on equity (9.99%)
  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year EPS growth (26.9%)
  • •Strong 3-year revenue growth (23.6%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,071.49 ₹1,045.97 ₹1,011.09 ₹985.57 ₹950.69 ₹925.17 ₹890.29
Fibonacci ₹1,045.97 ₹1,022.9 ₹1,008.64 ₹985.57 ₹962.5 ₹948.24 ₹925.17
Camarilla ₹992.81 ₹987.27 ₹981.74 ₹985.57 ₹970.66 ₹965.13 ₹959.59

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+139.91%

1 Week

-8.96%

1 Month

+7.89%

3 Months

+6.97%

6 Months

+28.18%

1 Year

+149.35%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹125.26

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

13.46%

Net margin 14.24% × asset turnover 0.7x × equity multiplier 1.35x

Company Overview

Sector

Healthcare

Market Cap

₹2,172 Cr

P/E (TTM)

50.7

ROE

9.99%

Book Value

₹156.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.

TopFund Analysis

Sakar Healthcare Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Valuation (11/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (30.0%); low return on equity (9.99%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

65/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

93

Valuation

11

Cash Flow

58

Corporate Governance

43

Momentum

71

Institutional Ownership

48

Business Quality

72

Risk & Volatility

73

Liquidity

61

From Screener.in

  • +Company has reduced debt.
  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 23.1% CAGR over last 5 years
  • −Stock is trading at 6.28 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Promoter holding has decreased over last quarter: -0.82%
  • −Company has a low return on equity of 7.50% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Sakar Healthcare Q2 FY27 revenue rose 52% to ₹87.4 crore; EBITDA up 114%, PAT up 149%, oncology expanded.

Q2FY27 earnings conference call audio recording uploaded on October 27, 2026; transcript to follow.

Sakar Healthcare shared Q2 and H1FY27 results: revenue up 52%, EBITDA 114%, PAT 149%.

Press Release 26 Oct

Sakar reported Q2/H1 FY27 results; revenue up 53%, EBITDA 114%, PAT 149%, with commercial supplies starting.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 34 37 43 41 43 43 50 53 58 70 71 73 87
Expenses + 25 28 32 30 31 32 35 40 46 52 45 52 63
Operating Profit 9 9 11 11 12 12 16 13 11 19 26 21 24
OPM % 27.0% 24.0% 25.0% 26.0% 27.0% 27.0% 31.0% 24.0% 20.0% 26.0% 37.0% 29.0% 28.0%
Other Income + 1 0 1 0 0 0 0 0 1 1 0 2 0
Interest 2 2 2 1 2 1 4 2 2 2 2 2 2
Depreciation 4 4 5 5 5 5 5 6 6 6 6 7 7
Profit before tax 4 3 5 5 5 5 6 5 5 11 18 15 16
Tax % 13.0% 31.0% 35.0% 49.0% 6.0% 17.0% 8.0% 13.0% 15.0% 6.0% 39.0% 29.0% 29.0%
Net Profit + 4 2 3 2 5 5 6 5 5 10 11 10 11
EPS in Rs 2 1 1 1 2 2 3 2 2 5 5 5 5
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 11 11 6 6 26 17 17 28 35 62 42 38 52

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 35 41 44 53 68 83 95 128 133 153 178 251 302
Expenses + 27 33 34 40 51 63 72 99 100 115 128 182 211
Operating Profit 8 8 10 13 17 20 23 29 33 38 50 69 90
OPM % 22.0% 20.0% 23.0% 24.0% 25.0% 24.0% 24.0% 23.0% 25.0% 25.0% 28.0% 27.0% 30.0%
Other Income + 0 0 1 0 1 2 1 2 5 3 1 2 2
Interest 3 3 3 3 2 2 2 3 6 8 9 8 8
Depreciation 2 3 3 4 6 7 8 10 15 18 21 24 25
Profit before tax 2 3 5 6 9 12 13 19 17 16 22 40 60
Tax % 24.0% 22.0% 30.0% 38.0% 28.0% 21.0% 19.0% 20.0% 24.0% 27.0% 19.0% 23.0% —
Net Profit + 2 2 3 4 7 10 11 15 13 12 18 30 43
EPS in Rs 2 3 3 3 4 6 7 9 7 5 8 14 19
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth 18 18 7 20 29 — 14 35 4 15 16 42 48

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 7 11 25 39 57 66 83 110 154 241 264 302 324
Borrowings + 25 22 24 11 11 17 43 93 119 79 86 71 46
Other Liabilities + 11 10 11 18 15 17 37 47 44 47 43 86 124
Total Liabilities 50 51 71 81 97 115 178 268 336 389 415 481 516
Fixed Assets + 36 37 49 53 64 66 69 205 267 314 309 326 334
CWIP 0 0 0 0 9 13 49 1 6 0 17 4 6
Investments 0 0 0 0 0 0 0 7 3 0 0 0 0
Other Assets + 14 14 22 28 25 36 60 55 60 74 90 151 176
Total Assets 50 51 71 81 97 115 178 268 336 389 415 481 516
Equity Capital 8 8 11 12 15 15 16 17 19 22 22 22 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 4 9 2 5 16 19 15 36 33 24 34 49
Cash from Investing Activity + -1 -4 -14 -8 -25 -22 -47 -90 -74 -52 -31 -28
Cash from Financing Activity + -3 -6 13 -13 9 3 32 55 41 27 -3 -21
Net Cash Flow 1 -1 0 -16 0 0 0 0 0 0 0 0
Free Cash Flow 4 5 -13 -4 -9 -4 -32 -62 -49 -35 2 21
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 60 117 30 51 104 110 67 120 113 72 73 77

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 53.15% → 51.7%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 22.47% 22.71% 22.71% 22.8% 21.96% 21.85% 22.48% 22.41% 22.73% 22.87% 23.98% 24.04%
Promoters 53.15% 53.15% 53.15% 53.15% 53.58% 53.58% 52.86% 52.86% 52.86% 52.86% 52.52% 51.7%
FII 13.76% 13.52% 13.52% 13.42% 13.58% 13.61% 13.41% 13.31% 13.05% 12.94% 12.13% 12.34%
DII 10.62% 10.62% 10.62% 10.62% 10.88% 10.97% 11.25% 11.43% 11.36% 11.32% 11.37% 11.92%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sakar Healthcare Limited (this stock) 2,172 50.7 6.26 9.99%
Panacea Biotec Ltd 2,171 — 2.6 -2.42%
Dishman Carbo Amcis Ltd 2,183 151.0 0.33 1.58%
Sai Parenterals Limited 2,189 87.8 4.42 4.88%
Vimta Labs Limited 2,230 36.7 6.46 13.5%
Indoco Remedies Ltd. 2,079 — 2.03 -9.36%
Windlas Biotech Limited 2,067 31.1 3.64 12.2%

Which Mutual Funds Hold Sakar Healthcare Limited?

Frequently Asked Questions about Sakar Healthcare Limited

Community Sentiment

What are other investors saying about Sakar Healthcare Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.